NEWS AND EVENTS

As the focus on the COVID-19 pandemic shifts to raising the number of vaccinated people around the world, U.S. researchers, funded by the NIH, are undertaking a large new clinical trial to find effective treatments, in the belief that while controllable, SARS-Cov-2 and its variants will continue to cause endemic disease in many parts of the world.

Constant Expands Patent Portfolio for TXA127 and for Stroke

TXA302 Shows Positive Activity in 3 models of stroke recovery

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company’s lead compound, TXA127, for the treatment of laminin-­‐deficient congenital muscular dystrophy (LAMA2 MD or MDC1A).

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease (RPD) designation for the company’s drug candidate TXA127 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.

Company Has “Green Light” to Proceed with Phase 2 Study, Planned to Initiate in Early 2016

TXA127 Shows Positive Activity in Fibrilin Model of Marfan Syndrome

Results Warrant Further Research into TXA127 as a Comprehensive Single Agent Therapeutic for this Genetic Muscle Disease

Noted ALS Researcher, Robert H. Brown, Jr., Ph.D., M.D., Joins Tarix Orphan Strategic Advisory Board Cambridge, MA

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the company’s lead product candidate, TXA127, has achieved positive results